Home    Back

Lubiprostone    (DrugBank: Lubiprostone)

4 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease4
13Multiple sclerosis/Neuromyelitis optica1
290Chronic nonspecific multiple ulcers of the small intestine1
299Cystic fibrosis1

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 2,123 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-UMIN000022023
2016/05/1010/05/2016A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora- Parkinson diseaseChronic constipationStudy drug group:
A 12-week administration of lubiprostone 24 microgrum (adjustable) twice daily after switching from magnesium oxide

Control group:
Continuous administration of magnesium oxide at the same dosage regimen as before the enrollmen		Dokkyo Medical UniversityNULLComplete: follow-up complete20years-old90years-oldMale and Female64Not selectedJapan
2JPRN-UMIN000022022
2016/05/1010/05/2016A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson diseaseA randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease - A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease Parkinson diseaseChronic constipationStudy drug group:
A 12-week administration of lubiprostone 24 microrgrum (adjustable) twice daily after switching from magnesium oxide

Control group:
Continuous administration of magnesium oxide at the same dosage regimen as before the enrollment		Dokkyo Medical UniversityNULLComplete: follow-up complete20years-old90years-oldMale and Female64Not selectedJapan
3NCT00669461
(ClinicalTrials.gov)		June 200928/4/2008Lubiprostone as a Treatment for Constipation in Parkinson's DiseaseLubiprostone as a Treatment for Constipation in Parkinson's DiseaseConstipation;Parkinson's DiseaseDrug: LubiprostoneUniversity of ArkansasTakedaTerminated50 Years85 YearsAll1N/AUnited States
4NCT00908076
(ClinicalTrials.gov)		February 200921/5/2009Amitiza in Constipation Associated With PD (Parkinson's Disease)Randomized Double-Blind Placebo-Controlled Trial of Lubiprostone in the Treatment of Constipation Associated With Parkinson's DiseaseParkinson's DiseaseDrug: LUBIPROSTONEBaylor College of MedicineUniversity of South FloridaCompleted18 Years85 YearsAll78Phase 4United States

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3,050 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01236534
(ClinicalTrials.gov)		November 20104/11/2010Lubiprostone in Patients With Multiple Sclerosis Associated ConstipationSingle-center, Randomized, Double-blind, Placebo-controlled, Parallel-groups Study of Lubiprostone in Patients With Multiple Sclerosis-Associated ConstipationMultiple Sclerosis;ConstipationDrug: Lubiprostone;Drug: PlaceboUniversity of RochesterTakedaCompleted18 YearsN/AAll21Phase 4United States

290. Chronic nonspecific multiple ulcers of the small intestine    [ 1 clinical trial,   1 drug,   (DrugBank: 1 drug),   1 drug target gene,   1 drug target pathway]
Searched query = "Chronic nonspecific multiple ulcers of the small intestine", "Nonspecific multiple ulcers in the small intestine"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 1 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-UMIN000030327
2017/12/2522/12/2017Proof-of-concept clinical trial of lubiprostone's effect on chronic enteropathy associated with SLCO2A1Proof-of-concept clinical trial of lubiprostone's effect on chronic enteropathy associated with SLCO2A1 - LEAC study Nonspecific multiple ulcers in the small intestine unrelated to NSAID (Chronic enteropathy associated with SLCO2A1: CEAS)lubiprostone(12 micrograms) for 8 weeksFujita Health University, Department of GastroenterologyNULLComplete: follow-up complete20years-old80years-oldMale and Female8Phase 1;Phase 2Japan

299. Cystic fibrosis    [ 1,592 clinical trials,   1,539 drugs,   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways]
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 1,592 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00706004
(ClinicalTrials.gov)		July 200825/6/2008Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic FibrosisShort Term Safety and Efficacy of Lubiprostone in Adults With Cystic FibrosisConstipation;Cystic FibrosisDrug: lubiprostoneUniversity of ArkansasTakeda Pharmaceuticals North America, Inc.Completed18 YearsN/AAll9N/AUnited States

Back to top